{
    "clinical_study": {
        "@rank": "85746", 
        "arm_group": [
            {
                "arm_group_label": "Cohort 1 Every 4 Weekly", 
                "arm_group_type": "Experimental", 
                "description": "subjects who have received no treatment for MF in at least two weeks will be assigned to treatment with single agent PRM-151 at a dose of 10 mg/kg administered IV on Days 1, 3, and 5 of Cycle 1 and Day 1 of each subsequent 28 day cycle for six cycles"
            }, 
            {
                "arm_group_label": "Cohort 2 Weekly", 
                "arm_group_type": "Experimental", 
                "description": "subjects on a stable dose of ruxolitinib for at least 12 weeks, with no improvement in spleen during the last four weeks will be assigned to receive PRM-151 in combination with ruxolitinib at a dose of 10 mg/kg administered IV on Days 1, 3, 5, 8, 15, and 22 of Cycle 1 and Days 1, 8, 15 and 22 of each subsequent 28 day cycle for six cycles."
            }, 
            {
                "arm_group_label": "Cohort 2 Every 4 Weekly", 
                "arm_group_type": "Experimental", 
                "description": "subjects on a stable dose of ruxolitinib for at least 12 weeks, with no improvement in spleen during the last four weeks will be assigned to receive PRM-151 in combination with ruxolitinib at a dose of 10 mg/kg administered IV on Days 1, 3, and 5 of Cycle 1 and Day 1 of each subsequent 28 day cycle for six cycles"
            }, 
            {
                "arm_group_label": "Cohort 1 weekly", 
                "arm_group_type": "Experimental", 
                "description": "subjects who have received no treatment for MF in at least two weeks will be  assigned to treatment with single agent PRM-151 at a dose of 10 mg/kg IV on Days 1, 3, 5, 8, 15, and 22 of Cycle 1 and Days 1, 8, 15 and 22 of each subsequent 28 day cycle for six cycles"
            }
        ], 
        "brief_summary": {
            "textblock": "PRM-151 is an investigational drug that is being developed for possible use in the treatment\n      of myelofibrosis (MF), a disease in which the bone marrow, which is the organ in the body\n      that makes blood cells, is replaced by fibrosis, or excess scar tissue.\n\n      The purpose of this study is to gather information on whether PRM-151 has an effect on the\n      MF disease, whether it is safe in patients with MF, and how well it is tolerated."
        }, 
        "brief_title": "A Phase 2 Study Of PRM-151 In Subjects With Myelofibrosis", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Primary Myelofibrosis", 
            "Post-Polycythemia Vera Myelofibrosis", 
            "Post-Essential Thrombocythemia Myelofibrosis"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Primary Myelofibrosis", 
                "Polycythemia", 
                "Polycythemia Vera", 
                "Thrombocythemia, Essential", 
                "Thrombocytosis"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is an open-label, Simon two stage, Phase 2 study to determine the efficacy and safety\n      of two different dose schedules of PRM-151 in subjects with PMF and post ET/PV MF. There are\n      two treatment cohorts, each assigned to one of two dose schedules of PRM-151. Subjects will\n      be assigned to a weekly or every four week dosing schedule by the investigator based on\n      their ability to visit the study site on a weekly basis.  This is an adaptive design as\n      defined in FDA Draft Guidance for Industry: Adaptive Design Clinical Trials for Drugs and\n      Biologics, February 2010.  Modifications to dose levels, schedule, or regimen may be made in\n      Stage 2 based on data from Stage 1."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  1. Subjects must be \u226518 years of age at the time of signing the Informed Consent Form\n             (ICF);\n\n             2. Subjects must voluntarily sign an ICF;\n\n             3. Subjects must have a pathologically confirmed diagnosis of PMF as per the WHO\n             diagnostic criteria (see Appendix C) or post ET/PV MF (note that all diagnoses must\n             include the presence of at least Grade 2 marrow fibrosis according to the European\n             Consensus on Grading of Bone Marrow Fibrosis (Appendix D) with intermediate -1,\n             intermediate -2, or high risk disease according to the International Working Group\n             for Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) Dynamic\n             International Prognostic Scoring System (see Appendix E);\n\n             4. A biopsy must be performed within four weeks prior to Cycle 1 Day 1 treatment to\n             establish the baseline fibrosis score;\n\n             5. Subjects must have an Eastern Cooperative Oncology Group (ECOG) Performance Status\n             of 0-2.  (Appendix F);\n\n             6. Life expectancy of at least six months;\n\n             7. At least two weeks must have elapsed between the last dose of any MF-directed drug\n             treatments for myelofibrosis (including investigational therapies) and study\n             enrollment, except for ruxolitinib for Cohort 2 (see Inclusion Criteria 11);\n\n             8. Recovery to \u2264 Grade 1 or baseline of any toxicities due to prior systemic\n             treatments, excluding alopecia;\n\n             9. Women of child bearing potential (WCBP), defined as a sexually mature woman not\n             surgically sterilized or not post-menopausal for at least 24 consecutive months if\n             \u226455 years or 12 months if >55 years, must have a negative serum pregnancy test within\n             four weeks prior to the first dose of study drug and must agree to use adequate\n             methods of birth control throughout the study.  Adequate methods of contraception\n             include use of oral contraceptives or Depo-Provera, with an additional barrier method\n             (diaphragm with spermicidal gel or condoms with spermicide), double-barrier methods\n             (diaphragm with spermicidal gel and condoms with spermicide), partner vasectomy, and\n             total abstinence.\n\n             10. Ability to adhere to the study visit schedule and all protocol requirements;\n\n             11. For Cohort 2 (PRM-151 added to ruxolitinib) Subjects only: Must have been on a\n             stable dose of ruxolitinib treatment for at least 12 weeks with no further\n             improvement in splenomegaly for at least four weeks;\n\n             12. Must have adequate organ function as demonstrated by the following:\n\n               -  ALT (SGPT) and/or AST (SGOT) \u2264 3x upper limit of normal (ULN), or \u2264 4 x ULN (if\n                  upon judgment of the treating physician, it is believed to be due to\n                  extramedullary hematopoiesis [EMH] related to MF);\n\n               -  Direct bilirubin \u2264 1.5 x ULN; or \u2264 2x ULN (if upon judgment of the treating\n                  physician, it is believed to be due to EMH related to MF);\n\n               -  Serum creatinine \u2264 2.5 mg/dL x ULN.\n\n        Exclusion Criteria:\n\n          -  1. Other invasive malignancies within the last 3 years, except non-melanoma skin\n             cancer and localized cured prostate and cervical cancer;\n\n             2. History of stroke, unstable angina, myocardial infarction, or ventricular\n             arrhythmia requiring medication or mechanical control within the last 6 months;\n\n             3. Presence of active serious infection;\n\n             4. Any serious, unstable medical or psychiatric condition that would prevent, (as\n             judged by the Investigator) the subject from signing the informed consent form or any\n             condition, including the presence of laboratory abnormalities, which places the\n             subject at unacceptable risk if he/she were to participate in the study or confounds\n             the ability to interpret data from the study;\n\n             5. Known history of human immunodeficiency virus (HIV), or known active hepatitis A,\n             B, or C infection;\n\n             6. Organ transplant recipients other than bone marrow transplant;\n\n             7. Women who are pregnant or lactating."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "104", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 29, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01981850", 
            "org_study_id": "PRM-151G-101"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Cohort 1 Every 4 Weekly", 
                    "Cohort 2 Weekly", 
                    "Cohort 2 Every 4 Weekly", 
                    "Cohort 1 weekly"
                ], 
                "description": "recombinant human pentraxin-2", 
                "intervention_name": "PRM-151", 
                "intervention_type": "Biological", 
                "other_name": "recombinant human pentraxin-2"
            }, 
            {
                "arm_group_label": [
                    "Cohort 2 Weekly", 
                    "Cohort 2 Every 4 Weekly"
                ], 
                "intervention_name": "Ruxolitinib", 
                "intervention_type": "Drug", 
                "other_name": "Jakafi"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": "fibrosis", 
        "lastchanged_date": "January 8, 2014", 
        "location": [
            {
                "contact": {
                    "last_name": "Ruben Mesa, MD", 
                    "phone": "480-301-4961"
                }, 
                "contact_backup": {
                    "last_name": "Vineta Ghurye", 
                    "phone": "480-301-9191"
                }, 
                "facility": {
                    "address": {
                        "city": "Scottsdale", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85259"
                    }, 
                    "name": "Mayo Clinic Arizona"
                }, 
                "investigator": {
                    "last_name": "Ruben Mesa, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Jason Gotlib, MD", 
                    "phone": "650-725-0744"
                }, 
                "contact_backup": {
                    "last_name": "Andrea Linder, MD", 
                    "phone": "650-725-4047"
                }, 
                "facility": {
                    "address": {
                        "city": "Palo Alto", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94304"
                    }, 
                    "name": "Stanford Cancer Institute"
                }, 
                "investigator": {
                    "last_name": "Jason Gotlib, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "rub9018@med.cornell.edu", 
                    "last_name": "Ruth Bauman, RN", 
                    "phone": "646-962-2700"
                }, 
                "contact_backup": {
                    "email": "ritchie@med.cornell.edu", 
                    "last_name": "Ellen Ritchie, MD", 
                    "phone": "646-962-2700"
                }, 
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10065"
                    }, 
                    "name": "Weil Cornell Medical Center"
                }, 
                "investigator": {
                    "last_name": "Ellen Ritchie, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Sarah.han@mssm.edu", 
                    "last_name": "Sarah Han", 
                    "phone": "212-241-9185"
                }, 
                "contact_backup": {
                    "email": "Carrie.newsom@mssm.edu", 
                    "last_name": "Carrie Newsom, RN", 
                    "phone": "212-241-9185"
                }, 
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10029"
                    }, 
                    "name": "Mount Sinai Medical Center"
                }, 
                "investigator": {
                    "last_name": "John Mascarenhas, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Srdan Verstovsek, MD", 
                    "phone": "713-745-3429"
                }, 
                "contact_backup": {
                    "last_name": "Heather Schneider, RN", 
                    "phone": "713-792-4478"
                }, 
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77030"
                    }, 
                    "name": "MD Anderson Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Srdan Verstovsek, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Lynda Foltz, MD", 
                    "phone": "604-684-5794"
                }, 
                "contact_backup": {
                    "last_name": "Gail Viciente", 
                    "phone": "604-682-2344"
                }, 
                "facility": {
                    "address": {
                        "city": "Vancouver", 
                        "country": "Canada", 
                        "state": "British Columbia", 
                        "zip": "V6Z 2A5"
                    }, 
                    "name": "Providence Health Care"
                }, 
                "investigator": {
                    "last_name": "Lynda Foltz, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Vikas Gupta, MD", 
                    "phone": "416-946-4521"
                }, 
                "contact_backup": {
                    "last_name": "Jayalakshm Ramanna", 
                    "phone": "416-946-4501", 
                    "phone_ext": "7808"
                }, 
                "facility": {
                    "address": {
                        "city": "Toronto", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "M5T 2M9"
                    }, 
                    "name": "The Princess Margaret Cancer Centre"
                }, 
                "investigator": {
                    "last_name": "Vikas Gupta, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Canada"
            ]
        }, 
        "number_of_arms": "4", 
        "official_title": "A Phase 2, Open-Label, Prospective Study Of PRM-151 In Subjects With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV MF), Or Post-Essential Thrombocythemia MF (Post-ET MF)", 
        "overall_official": {
            "affiliation": "Promedior, Inc.", 
            "last_name": "Elizabeth G Trehu, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Canada: Health Canada"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Overall response rate according to International Working Group consensus criteria for treatment response in myelofibrosis with myeloid metaplasia", 
            "safety_issue": "No", 
            "time_frame": "6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01981850"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Incidence of adverse events (AEs), serious adverse events (SAEs), and changes in laboratory test results", 
                "safety_issue": "No", 
                "time_frame": "up to 28 weeks"
            }, 
            {
                "measure": "Change in bone marrow fibrosis according to European Consensus on Grading of Bone Marrow Fibrosis", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "Change in the modified Myeloproliferative Neoplasms Symptom Assessment Form (MPN-SAF) Score", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "Duration of response", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "Pharmacokinetic (PK) parameters including Cmax (maximum drug concentration), tmax (time to maximum concentration, area under the curve (AUC), clearance, and volume of distribution.", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }
        ], 
        "source": "Promedior, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Promedior, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}